GlassScriptPhysician profile
Shehzad Jinnah
NPI 1396734042
$4,186.00
in general payments reported to CMS, 2019-2025
32 companies · $625 in 2025
The $625 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $606 · 2021: $825 · 2022: $404 · 2023: $840 · 2024: $658 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,116 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.11 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $622.20 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $480.86 | 2021-2025 | |
| Pfizer INC. | $471.76 | 2019-2025 | |
| Amarin Pharma, INC. | $425.24 | 2020-2021 | |
| Amgen INC. | $322.66 | 2020-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $299.70 | 2019-2024 | Airsupra, Farxiga |
| Exact Sciences Corporation | $258.84 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $187.03 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.56 | 2019-2024 | Jardiance |
| Boston Scientific Corporation | $142.22 | 2023 | Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $124.33 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $97.63 | 2023-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $72.59 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $58.44 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $52.18 | 2024-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $45.12 | 2024 | Voquezna |
| Heartflow, INC. | $42.57 | 2025 | |
| Medicure Pharma INC. | $39.77 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.48 | 2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $23.50 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $23.30 | 2024 | |
| Axsome Therapeutics, INC. | $21.80 | 2025 | Auvelity |
| Eisai INC. | $19.32 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.00 | 2024 | Trintellix |
| Glaxosmithkline, LLC. | $18.08 | 2025 | Shingrix |
| Gilead Sciences, INC. | $16.82 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.83 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.46 | 2021 | |
| Zealand Pharma US, INC. | $15.40 | 2021 | |
| Celgene Corporation | $14.85 | 2023 | Eliquis |
| Philips North America LLC | $14.45 | 2020 | |
| Astellas Pharma US INC | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shehzad Jinnah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.